Kim et al. BMC Cancer 2012, 12:147 http://www.biomedcentral.com/1471-2407/12/147 Received: 7 December 2011 Accepted: 13 April 2012 Published: 13 April 2012 References 1. American Cancer Society: Cancer Facts and Figures. 2010 [http://www. cancer.org]. 2. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002, 360:505-515. 3. Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, Kuppusamy P: Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci USA 2006, 103:3914-3919. 4. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6. 5. Medici V, Sturniolo GC: Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs 2008, 11:592-606. 6. Juarez JC, Betancourt O Jr, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Donate F: Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 2006, 12:4974-4982. 7. Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG: Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecol Oncol 2011, 122:183-189. 8. Koto KS, Lescault P, Brard L, Kim K, Singh RK, Bond J, Illenye S, Slavik MA, Ashikaga T, Saulnier Sholler GL: Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int J Oncol 2011, 38:1329-1341. 9. Ishida S, McCormick F, Smith-McCune K, Hanahan D: Enhancing tumor- specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583. 10. Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, Teknos TN: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 2010, 9:206. 11. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, et al: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000, 6:1-10. 12. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S: A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008, 86:383-389. 13. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003, 9:1666-1672. 14. Creech RH, Shah MK, Catalano RB, Dierks K, Dayal H, Goldberg-Alberts R: Phase II study of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy. Cancer Treat Rep 1985, 69:1271-1273. 15. Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ, D’Hondt V: Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet 2008, 278:457-462. 16. Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992, 19:670-686. 17. Garcia AA, Morgan R, McNamara M, Scudder S, Tsao-Wei D, Groshen S, Frgala T, Kim Y, Reynolds CP: Phase II trial of fenretinide (4-HPR) in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Consortium trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004, 22:5056. 18. Appierto V, Tiberio P, Villani MG, Cavadini E, Formelli F: PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS- dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009, 30:824-831. 19. Koedrith P, Seo YR: Enhancement of the efficacy of mitomycin c- mediated apoptosis in human colon cancer cells with RNAi-based Page 9 of 10 thioredoxin reductase 1 deficiency. Experimental and Therapeutic Medicine 2011, 2:873-878. 20. Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B: Ferredoxin reductase affects p53-dependent, 5- fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001, 7:1111-1117. 21. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE: Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 1989, 49:3844-3848. 22. Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116. 23. Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS: Organometallic Iron(III)-Salophene Exerts Cytotoxic Properties in Neuroblastoma Cells via MAPK Activation and ROS Generation. PLoS One 2011, 6:e19049. 24. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, Arihiro K: Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol 2006, 208:319-326. 25. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML: Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 1995, 130:157-167. 26. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741. 27. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM: Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006, 66:4863-4871. 28. Dusre L, Mimnaugh EG, Myers CE, Sinha BK: Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 1989, 49:511-515. 29. Gouaze V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieu-Abadie N: Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol 2001, 60:488-496. 30. Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C: Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007, 6:1031-1038. 31. Hou G, Dick R, Abrams GD, Brewer GJ: Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 2005, 146:299-303. 32. Shiraha Y, Sakai K, Teranaka T: Clinical trials of mitomycin C, a new antitumor antibiotic; preliminary report of results obtained in 82 consecutive cases in the field of general surgery. Antibiot Annu 1958, 6:533-540. 33. Aoki Y, Kurata H, Watanabe M, Fujita K, Tanaka K: Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 2004, 27:461-464. 34. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA: Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996, 53:1017-1025. 35. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338. 36. Prefontaine M, Donovan JT, Powell JL, Buley L: Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Gynecol Oncol 1996, 61:249-252. 37. Wu JM, DiPietrantonio AM, Hsieh TC: Mechanism of fenretinide (4-HPR)- induced cell death. Apoptosis 2001, 6:377-388. 38. Gupte A, Mumper RJ: Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009, 35:32-46. 39. Waris G, Ahsan H: Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006, 5:14. 40. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P: Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004, 53:209-219. 41. Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS- mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009, 8:579-591.